RecruitingNCT05849038
Baricitinib or placebo and brain mechanisms of depression in people with HIV
About this title
Read the official source — NCT05849038Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Atlanta and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 11, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Emory University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05849038
- Official title
Show the full official title
The Role of Inflammation in Central Nervous System (CNS) Mechanisms of Anhedonia and Psychomotor Slowing in Depressed People With HIV
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Atlanta
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Emory University, a university.
Does this study involve medication?
Yes. The study involves medication, including Baricitinib.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
